OBJECTIVE: Abnormal expression of several biomarkers might predict disease prognosis and response to chemotherapy in patients with epithelial ovarian cancer (EOC). However, the published data are inconsistent. METHODS: Eligible studies that investigated the association between survival or response to platinum-based chemotherapy in EOC and the expression status of Bcl-2, EGFR, GST, LRP, p16, p21, P-gp and TNF-α were identified by an electronic search of PubMed and Embase. The measures of interest were hazard ratio (HR) for survival or risk ratio for chemotherapy response. A meta-analysis was performed using the fixed-effect or random-effect models. RESULTS: The number of eligible studies analyzed was 27 for Bcl-2, 22 for EGFR, 29 for GST, 12 for LRP, 16 for p16, 22 for p21, 27 for P-gp and three for TNF-α. A meta-analysis showed that high EGFR and P-gp expression was associated with poor overall survival (OS) (pooled adjusted HR = 1.826 and HR = 1.822). Only high GST expression was associated with improved OS (HR = 0.780). Furthermore, high p16 and P-gp expression was associated with poor progression-free survival (PFS) (HR = 1.550 and HR = 2.136). High GST expression was associated with improved PFS (HR = 0.689). Among these factors, only LRP, P-gp and TNF-α were associated with response to platinum-based chemotherapy. CONCLUSIONS: The markers we analyzed are unlikely to be useful as predictors of prognosis and response to platinum-based chemotherapy in EOC patients in clinical practice.
OBJECTIVE: Abnormal expression of several biomarkers might predict disease prognosis and response to chemotherapy in patients with epithelial ovarian cancer (EOC). However, the published data are inconsistent. METHODS: Eligible studies that investigated the association between survival or response to platinum-based chemotherapy in EOC and the expression status of Bcl-2, EGFR, GST, LRP, p16, p21, P-gp and TNF-α were identified by an electronic search of PubMed and Embase. The measures of interest were hazard ratio (HR) for survival or risk ratio for chemotherapy response. A meta-analysis was performed using the fixed-effect or random-effect models. RESULTS: The number of eligible studies analyzed was 27 for Bcl-2, 22 for EGFR, 29 for GST, 12 for LRP, 16 for p16, 22 for p21, 27 for P-gp and three for TNF-α. A meta-analysis showed that high EGFR and P-gp expression was associated with poor overall survival (OS) (pooled adjusted HR = 1.826 and HR = 1.822). Only high GST expression was associated with improved OS (HR = 0.780). Furthermore, high p16 and P-gp expression was associated with poor progression-free survival (PFS) (HR = 1.550 and HR = 2.136). High GST expression was associated with improved PFS (HR = 0.689). Among these factors, only LRP, P-gp and TNF-α were associated with response to platinum-based chemotherapy. CONCLUSIONS: The markers we analyzed are unlikely to be useful as predictors of prognosis and response to platinum-based chemotherapy in EOC patients in clinical practice.
Authors: Amanda Psyrri; Mohamad Kassar; Ziwei Yu; Aris Bamias; Paul M Weinberger; Sonia Markakis; Diane Kowalski; Robert L Camp; David L Rimm; Meletios A Dimopoulos Journal: Clin Cancer Res Date: 2005-12-15 Impact factor: 12.531
Authors: Y Dong; M D Walsh; M A McGuckin; B G Gabrielli; M C Cummings; R G Wright; T Hurst; S K Khoo; P G Parsons Journal: Int J Cancer Date: 1997-02-20 Impact factor: 7.396
Authors: Aristotelis Bamias; Vasiliki Koutsoukou; Evangelos Terpos; Marinos L Tsiatas; Christina Liakos; Ourania Tsitsilonis; Alexandros Rodolakis; Zannis Voulgaris; G Vlahos; Theocharis Papageorgiou; G Papatheodoridis; A Archimandritis; A Antsaklis; M A Dimopoulos Journal: Gynecol Oncol Date: 2007-11-26 Impact factor: 5.482
Authors: G Scambia; L Catozzi; P B Panici; G Ferrandina; F Coronetta; R Barozzi; G Baiocchi; L Uccelli; A Piffanelli; S Mancuso Journal: Am J Obstet Gynecol Date: 1993-01 Impact factor: 8.661